Milder chemo before transplant could help older blood cancer patients

NCT ID NCT05436561

Recruiting now Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a reduced-intensity chemotherapy regimen (fludarabine, busulfan, melphalan) before stem cell transplant in 61 patients aged 55 and older with myeloid cancers like AML, MDS, or CMML. The goal is to see if this gentler approach can improve disease-free survival while reducing side effects. Participants must have a matched or haploidentical donor and be in remission or early disease stages.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MBF-RIC (fludarabine, busulfan, melphalan)
What this could lead to: If successful, this milder chemo regimen could make stem cell transplants safer and more effective for older adults with myeloid cancers, potentially improving long-term survival without relapse.
What could go wrong: This is a small, early-phase study (61 participants) without a comparison group. The regimen may still cause serious side effects, and results may not apply to all patients or donors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DISEASE FREE SURVIVAL

Contacts and locations

Locations

Blood & Marrow Transplantation Center, RuiJin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China
Shanghai No 6 Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.